Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT

T Derlin, DG Sedding, J Dutzmann, A Haghikia… - European journal of …, 2018 - Springer
Purpose The chemokine receptor CXCR4 is a promising target for molecular imaging of
CXCR4+ cell types, eg inflammatory cells, in cardiovascular diseases. We speculated that a …

Imaging inflammation in atherosclerosis with CXCR4-directed 68Ga-pentixafor PET/CT: correlation with 18F-FDG PET/CT

M Kircher, J Tran-Gia, L Kemmer, X Zhang… - Journal of Nuclear …, 2020 - Soc Nuclear Med
CXC motif chemokine receptor 4 (CXCR4) is expressed on the surface of various cell types
involved in atherosclerosis, with a particularly rich receptor expression on macrophages and …

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review

P Windisch, DR Zwahlen, FL Giesel, E Scholz… - EJNMMI research, 2021 - Springer
Purpose Small molecules targeting fibroblast activation protein (FAP) have emerged as a
new group of tracers for positron emission tomography (PET) in 2018. While most of the …

[HTML][HTML] Clinical molecular imaging of pulmonary CXCR4 expression to predict outcome of pirfenidone treatment in idiopathic pulmonary fibrosis

T Derlin, B Jaeger, D Jonigk, RM Apel, J Freise… - Chest, 2021 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which two
antifibrotic drugs recently were approved. However, an unmet need exists to predict …

[HTML][HTML] PET imaging of macrophages in cardiovascular diseases

X Li, ZT Rosenkrans, J Wang, W Cai - American journal of …, 2020 - ncbi.nlm.nih.gov
Cardiovascular diseases (CVDs) have been the leading cause of death in United States.
While tremendous progress has been made for treating CVDs over the year, the high …

PET tracers for imaging cardiac function in cardio-oncology

JM Kelly, JW Babich - Current cardiology reports, 2022 - Springer
Abstract Purpose of Review Successful treatment of cancer can be hampered by the
attendant risk of cardiotoxicity, manifesting as cardiomyopathy, left ventricle systolic …

Heart-brain axis: pushing the boundaries of cardiovascular molecular imaging

M Khalil, HC Lau, JT Thackeray, N Mikail… - Journal of Nuclear …, 2024 - Elsevier
Despite decades of research, the heart-brain axis continues to challenge investigators
seeking to unravel its complex pathobiology. Strong epidemiologic evidence supports a link …

Nuclear medicine application of pentixafor/pentixather targeting CXCR4 for imaging and therapy in related disease

Z Chen, Q Xue, S Yao - Mini Reviews in Medicinal Chemistry, 2023 - ingentaconnect.com
CXC-motif chemokine receptor 4 (CXCR4) is a novel predictive biomarker for metastasis
and poor prognosis in individuals with malignancies. CXCL12 is the only cognate ligand of …

68Ga-Pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms

S Kraus, A Dierks, L Rasche, O Kertels… - Journal of Nuclear …, 2022 - Soc Nuclear Med
CXC motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and
treatment, as it is overexpressed in many solid and hematologic malignancies. This study …

Cardiovascular Molecular Imaging With Fluorine-19 MRI: The Road to the Clinic

RB van Heeswijk, WR Bauer, F Bönner… - Circulation …, 2023 - Am Heart Assoc
Fluorine-19 (19F) magnetic resonance imaging is a unique quantitative molecular imaging
modality that makes use of an injectable fluorine-containing tracer that generates the only …